Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Empyrean Diagnostics Inc.

This article was originally published in The Gray Sheet

Executive Summary

Agrees with Rilldale Ltd. of London, England, to share ownership of a new Swiss company with a 99-year license to manufacture and distribute EDI's proprietary HIV-1 test kit in Western Europe and Turkey. Rilldale, which "has committed a minimum of $2 mil." to the new company, will bear all start-up costs and oversee day-to- day operations. Empyrean, a U.S. subsidiary of Vancouver, British Columbia-based Socal Capital ("The Gray Sheet" Oct. 19, p. 9), will receive royalties on a per-item basis from the new firm, will receive a percentage of its gross sales, and will split the new company's net profits with Rilldale. Empyrean President and CEO Daniel Bland "is confident" that the Swiss firm will sell 25 million test kits at roughly $1.50 per kit by the end of 1994.

You may also be interested in...

Novartis In Line For Ofatumumab MS Approval In June

Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.

ICER Partnering With Aetion To Scale Up Use Of RWE In Value Assessments

Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.

‘Highly Questionable’ GMP Compliance In Pakistan Prompts New Licensing System

Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts